The third Annual Conference On Gynecologic Oncology and Prevention Oncology July 20-21, 2017 Chicago, Illinoid USA PPGYNO1 Poster Section @Athens Title.

Slides:

Advertisements

Similar presentations

Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine

Advertisements

Cross-border biomarker research of ovarian cancerCrossBiomark (HUSRB/1203/214/091) The project is co-financed by the European Union

A Simple Protocol for Identification of Heterophile Antibody Interferences in the Abbott AxSYM hCG Assay. P Giannopoulos, G Jones, E-M Lim Department of.

Strategic Center for Clinical Cancer Research Clinical Cancer Research using Emerging Advanced Technologies for Health Title Slide.

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

BIOC 401. Blood Sample To Detect Breast Cancer Cancer is actually a group of many related diseases that all have to do with cells. Cells are the very.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

Application of Proteomics in Cancer Study

Experimental Design and Biospecimens David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine.

Eleni Galani Medical Oncologist

ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010.

A new method to address cross-reactivity of antibodies

The use of human biospecimens in cancer research Christopher A. Moskaluk M.D., Ph.D. University of Virginia.

False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125 I. Prassas, D. Brinc, S. Farkona, F. Leung, A. Dimitromanolakis,

Director of Scientific Affairs

OF COLOREATAL CANCER USING SEROLOGIC TUMOR MARKERS DIAGNOSIS & MANAGEMENT.

Cathy Eng M.D., Salil Sethi M.D., George J.Chang, M.D., Miguel A. Rodriguez-Bigas, M.D., John M. Skibber, M.D., Jianjun Shen Ph.D., Jijiang Zhu Ph.D.,

Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Results 1.Miller JR, Siripurkpong P, Hawes J, Majdalawieh A, Ro HS, McLeod RS. The trans-10, cis-12 isomer of conjugated linoleic acid decreases adiponectin.

CHILDHOOD CANCER SURVIVORS OF MALIGNANT BONE TUMORS AND SOFT TISSUE SARCOMAS ARE AT RISK OF HOSPITALIZATION Cristian Gonzalez, BS, BA Jennifer Wright,

Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,

OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.

Arrays for Point-of-Care Early Cancer Detection James F. Rusling Departments of Chemistry & Cell Biology University of Connecticut and UCHC Storrs, CT,

About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events.

Understanding Cancer and Related Topics Understanding Cancer Developed by: Lewis J. Kleinsmith, Ph.D. Donna Kerrigan, M.S. Jeanne Kelly Brian Hollen Illustrates.

Overexpression of Serine Proteases in Ovarian Cancer Shelley Campeau Cellular and Developmental Biology Major University of California at Santa Barbara.

Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital.

Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.

Lecture Fifteen Biomedical Engineering for Global Health.

Novel blood and tissue Biomarkers for Breast and Prostate Cancers

San Antonio Breast Cancer Symposium – December 6-10, 2016

Figure e-1 A. Detection of anti-TIF1-γ antibody.

SURGICAL ONCOLOGY AND TUMOR MARKERS

Lab# 5 Western Blot BCH 462[practical].

OMICS Journals are welcoming Submissions

Samantha Knott October 7th, 2017

Table 2. Association between histology grade, lymph node status,

Douglas A. Plager, PhD, Ellen A. Weiss, Gail M. Kephart, BS, Robert M

From: Mitochondrial Localization and Ocular Expression of Mutant Opa3 in a Mouse Model of 3-Methylglutaconicaciduria Type III Invest. Ophthalmol. Vis.

Blot, Blot, Western Baby Kristin B. Dupre June 30th, 2011.

Techniques for measuring minimal residual disease in leukemia

Performance Comparison of CA125 and the Combination of the Other Serum Biomarkers for the Early Detection of the Ovarian Cancer Hye-Jeong Song1,3,

Samuel Kirkeng 7 December, 2017

Novel Technique for Early Detection of Pancreatic Cancer

Journal of Allergy and Clinical Immunology

Tbilisi Oncodipensary - Tbilisi Cancer Center

Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma

Analysis of CDCP1 as a potential prostate cancer biomarker.

Analysis of CD151 and CD147 as potential prostate cancer biomarkers.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Chronic neutropenia mediated by Fas ligand

Radiology Technology Application Pre-view

Monitoring HPV vaccine impact in Connecticut

Volume 115, Issue 1, Pages (July 1998)

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Karin U. Schallreuter Journal of Investigative Dermatology

Volume 143, Issue 1, Pages e7 (July 2012)

Generation and Sequencing of Pulmonary Carcinoid Tumor Cell Lines

Volume 133, Issue 3, Pages (September 2007)

Title Presenting Author & Affiliation Co-Authors

Lab# 5 Western Blot BCH 462[practical].

QSOX1 is highly expressed in tumor cell lines but is not expressed in adjacent normal cells. QSOX1 is highly expressed in tumor cell lines but is not expressed.

Lin Mu, Ph. D. , Wei Zheng, Ph. D. , M. D. , Liang Wang, Ph. D

John Starr, MD, John H. Pruett, PhD, John W. Yunginger, MD, Gerald J

Douglas A. Plager, PhD, Ellen A. Weiss, Gail M. Kephart, BS, Robert M

Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma Abundance of proteins matching selected subcellular locations.

VEGF expression in neoplastic and normal prostate tissue.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Presentation transcript:

The third Annual Conference On Gynecologic Oncology and Prevention Oncology July 20-21, 2017 Chicago, Illinoid USA PPGYNO1 Poster Section @Athens Title Investigation and Verification of New Biomarkers for Ovarian Cancer with Proteolytic Variants of Blood Proteins Title Authors : 1 Song Nan Chow, MD, Ph.D ,National Taiwan University Hospital, Department of OBGYN . Min-Sheng General Hospital, Taoyuan, Taiwan . 2 Chin-hsiang Chien OncoLock Co., Ltd. , Taiwan12 ; Taiwan Foundation for the Development of Biomedical Technology.1,2 There is a lot of efforts on discovery of biomarkers for early detection of ovarian cancer. However, still no suitable biomarkers can be applied for early detection or prognostic prediction of ovarian cancers, especially by blood test. Tumor markers should meet the criteria as listed below: 1. Reflection of tumor burden; 2. Levels should be quantifiable before and after surgical operations; 3. It can be detected in the live tumor tissues; and 4. Low level or absence in normal tissues. The purpose of this study is to verify whether the variants of factors contained in plasma or serum of ovarian cancer patients are new blood protein biomarkers for ovarian cancers. We are interested to investigate whether proteolytic species in human blood samples can be biomarkers for diagnosis of ovarian cancer. A new proteomic methodology has been implemented to mine these biomarkers of ovarian cancer. Methods of Investigation: Proteomics and Western blot detection. p1

Western blot analysis for NB from ovarian cancer patient plasma sample Results of western blot analyses of blood samples from human subjects with various health conditions using an OncoLock antibody-1 . Western blot analysis for NB from ovarian cancer patient plasma sample 1 2 3 4 5 6 7 8 9 10 11 12 10% reducing gel Loadng: 0255 0255T T263 T264 T265 T266 T267 T268 T7 T21 Nr- Jimbo Nr- Leo 245 180 140 100 75 60 45 35 25 15 Blocking buffer: 1% BSA 1st Ab : pre-NB (25 kDa) (1/1000 ) 2 ∘ Ab: Donkey anti mouse (1/10000) Contact information: snchow@ntu.edu.tw chiench@ym.edu.tw

Found the New Biomarker for Ovarian Cancer : Detection and Monitoring The third Annual Conference On Gynecologic Oncology and Prevention Oncology July 20-21, 2017 Chicago, USA PPGYNO1 Poster Section @Athens Found the New Biomarker for Ovarian Cancer : Detection and Monitoring Please Contact : OncoLock Co. Ltd, magch.chien@gmail.com